National PBM Monograph Template

In the treatment of UA/NSTEMI, enoxaparin (Level of Evidence A), UFH (Level of Evidence A), and fondaparinux (Level of Evidence B) are acceptable Class I recommended anticoagulants for invasive or conservative strategies. Fondaparinux or enoxaparin should be continued until discharge, up to 8 days. Fondaparinux may be a preferable agent in patients in whom a conservative strategy is planned ... ................
................